Source-grounded facts extracted from BOSTON SCIENTIFIC CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BOSTON SCIENTIFIC CORP shareholders rejected Stockholder proposal to give shareholders ability to call special meeting at the 2026-04-30 meeting.
“(8) The stockholders did not approve the stockholder proposal titled “Give Shareholders the Ability to Call for a Special Shareholder Meeting.” For Against Abstain Broker Non-Votes 516,140,863 689,739,605 4,513,925 81,271,529”
BOSTON SCIENTIFIC CORP shareholders rejected Amendment to permit stockholders owning 25% to call special meeting at the 2026-04-30 meeting.
“(7) The stockholders did not approve the amendment of the Company’s Third Restated Certificate of Incorporation and Amended and Restated By-Laws to permit stockholders owning not less than 25% of the Company’s common stock to call a special meeting of stockholders. For Against Abstain Broker Non-Votes 1,095,371,430 20,945,183 94,077,780 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of certificate of incorporation to provide for exculpation of officers at the 2026-04-30 meeting.
“(6) The stockholders approved the amendment of the Company’s Third Restated Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law. For Against Abstain Broker Non-Votes 1,057,086,923 150,458,633 2,848,837 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of certificate of incorporation to remove supermajority voting provisions at the 2026-04-30 meeting.
“(5) The stockholders approved the amendment of the Company’s Third Restated Certificate of Incorporation to remove supermajority voting provisions. For Against Abstain Broker Non-Votes 1,189,271,431 17,774,053 3,348,909 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of Employee Stock Purchase Plan to increase shares reserved at the 2026-04-30 meeting.
“(4) The stockholders approved the amendment of the Company’s Employee Stock Purchase Plan to increase the number of shares reserved for issuance. For Against Abstain Broker Non-Votes 1,205,130,032 2,818,667 2,445,694 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-04-30 meeting.
“(3) The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. For Against Abstain Broker Non-Votes 1,169,955,769 116,874,243 4,835,910 0”
BOSTON SCIENTIFIC CORP shareholders approved Advisory vote on executive compensation at the 2026-04-30 meeting.
“(2) The stockholders approved, on an advisory basis, the compensation of the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting. For Against Abstain Broker Non-Votes 1,096,889,576 110,645,813 2,859,004 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Election of 10 director nominees at the 2026-04-30 meeting.
“(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified. Nominee For Against Abstain Broker Non-Votes David C. Habiger 1,037,805,652 169,730,106 2,858,635 81,271,529 Edward J. Ludwig 1,156,469,560 50,835,636 3,089,197 81,271,529 Michael F. Mahoney 1,113,612,016 93,613,027 3,169,350 81,271,529 Jessica L. Mega 1,196,020,676 11,532,045 2,841,672 81,271,529 Susan E. Morano 1,171,890,417 35,662,932 1,841,044 81,271,529 Cheryl Pegus 1,195,889,562 11,653,832 2,850,999 81,271,529 Cathy R. Smith 1,117,908,896 88,044,911 4,440,586 81,271,529 Christophe P. Weber 1,205,365,637 2,260,256 2,768,500 81,271,529 David S. Wichmann 1,198,736,185 8,393,038 3,265,170 81,271,529 Ellen M. Zane 1,150,092,668 56,753,553 3,548,172 81,271,529”
BOSTON SCIENTIFIC CORP: Stockholders approved amendments to the Third Restated Certificate of Incorporation to eliminate supermajority voting provisions, implement clarifying changes, and provide for officer exculpation under Delaware law (effective 2026-05-05).
“approved amendments (the “Charter Amendments”) to the Company’s Third Restated Certificate of Incorporation, as described in the Company’s definitive proxy statement for the Annual Meeting filed on March 18, 2026 (the “Proxy Statement”) to (a) eliminate supermajority voting provisions contained therein, as well as to eliminate certain inoperative provisions and implement other clarifying and correcting changes, and (b) provide for exculpation of certain of our officers in certain circumstances as permitted by Delaware law. The Charter Amendments became effective upon the filing of the Company’s Fourth Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on May 5, 2026.”
BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2026 results: revenue $5.203 billion, net income $1.341 billion or $0.90 per share (EPS), EPS $0.80.
“(EX-99.1) --- Boston Scientific announces results for first quarter 2026 Marlborough, Mass. (April 22, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational 1 and organic 2 basis, all compared to the prior year period. The”
BOSTON SCIENTIFIC CORP incurred term loan of up to $1.000 billion with Wells Fargo Bank, National Association maturing 364-day delayed draw.
“by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion”
BOSTON SCIENTIFIC CORP incurred revolving credit of $2.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the.
“On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP incurred revolving credit of $3.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing February 26, 2031.
“On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $6.000 billion (effective 2026-02-26).
“On February 26, 2026, the Company entered into a $6.000 billion term loan credit agreement (the “ Term Loan Credit Agreement ” and together with the 2026 Revolving Credit Agreement and the 364-Day Revolving Credit Agreement, the “ 2026 Credit Agreements ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into 364-Day Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $2.000 billion (effective 2026-02-26).
“On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into 2026 Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $3.000 billion (effective 2026-02-26).
“On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.”
BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Penumbra, Inc. (effective 2026-01-14).
“On January 14, 2026, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Penumbra, Inc., a Delaware corporation (“ Penumbra ”), providing for the merger of Merger Sub with and into Penumbra (the “ Merger ”), with Penumbra surviving the Merger as a wholly owned subsidiary of the Company.”
Jonathan Monson was appointed as Executive Vice President and Chief Financial Officer at BOSTON SCIENTIFIC CORP.
“Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025”
Daniel J. Brennan departed as Executive Vice President and Chief Financial Officer at BOSTON SCIENTIFIC CORP.
“On April 23, 2025, Boston Scientific Corporation (the “Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025”
BOSTON SCIENTIFIC CORP incurred senior notes of €650,000,000 with U.S. Bank Trust Company, National Association at 3.250% maturing due 2034.
“The Notes were issued pursuant to an indenture dated as of March 8, 2022 among AMS Europe, the Company and U.S. Bank Trust Company, National Association, as trustee (the “Indenture”). The Indenture contains covenants that restrict (i) the Company’s and AMS Europe’s ability, with certain exceptions, to merge or consolidate with another entity or transfer all or substantially all of its property and assets, and (ii) the Company’s and its Subsidiaries (as defined in the Indenture) ability, with certain exceptions, to incur liens.”
BOSTON SCIENTIFIC CORP incurred senior notes of €850,000,000 with U.S. Bank Trust Company, National Association at 3.000% maturing due 2031.
“The Notes were issued pursuant to an indenture dated as of March 8, 2022 among AMS Europe, the Company and U.S. Bank Trust Company, National Association, as trustee (the “Indenture”). The Indenture contains covenants that restrict (i) the Company’s and AMS Europe’s ability, with certain exceptions, to merge or consolidate with another entity or transfer all or substantially all of its property and assets, and (ii) the Company’s and its Subsidiaries (as defined in the Indenture) ability, with certain exceptions, to incur liens.”
Charles J. Dockendorff departed as Director at BOSTON SCIENTIFIC CORP.
“Charles J. Dockendorff informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders”
David C. Habiger was appointed as Director at BOSTON SCIENTIFIC CORP.
“appointed David C. Habiger, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective July 30, 2024.”
Cheryl Pegus was appointed as Director at BOSTON SCIENTIFIC CORP.
“appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.”
BOSTON SCIENTIFIC CORP: Amendment and restatement of By-Laws to provide for advance notice and universal proxy rule updates, including expanded disclosures, revised advance notice period, and compliance requirements for Rule 14a-19, effective May 2, 2024 (effective 2024-05-02).
“The By-Laws, as so amended and restated, became effective May 2, 2024.”
BOSTON SCIENTIFIC CORP reported the first quarter ended March 31, 2024 results: revenue $3.856 billion, net income $495 million or $0.33 per share, EPS $0.56 for the period.
“Document Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational 1 basis and 13.1 percent on an organic 2 basis, all compared to the”
BOSTON SCIENTIFIC CORP incurred senior notes of €2,000,000,000 aggregate principal amount with the several underwriters named in the Underwriting Agreement at 3.375% Senior Notes due 2029 and 3.500% Senior Notes due 2032 maturing 2029 and 2032.
“in connection with AMS Europe’s previously announced pricing of €2,000,000,000 aggregate principal amount of its senior notes. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase €750,000,000 in aggregate principal amount of 3.375% Senior Notes due 2029 and €1,250,000,000 in aggregate principal amount of 3.500% Senior Notes due 2032”
BOSTON SCIENTIFIC CORP entered into Underwriting Agreement with the several underwriters named in the Underwriting Agreement valued at €2,000,000,000 aggregate principal amount of its senior notes (effective 2024-02-22).
“On February 22, 2024, Boston Scientific Corporation (the “Company”), as guarantor, and American Medical Systems Europe B.V. (“AMS Europe”), its wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement, (as supplemented by the Terms Agreement, also dated February 22, 2024, the “Underwriting Agreement”), among the Company, AMS Europe and the several underwriters named in the Underwriting Agreement (the “Underwriters”), in connection with AMS Europe’s previously announced pricing of €2,000,000,000 aggregate principal amount of its senior notes.”
BOSTON SCIENTIFIC CORP reported financial results for the fourth quarter and full year ended December 31, 2023.
“On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.”
Emily Woodworth (Collins) was appointed as Senior Vice President, Global Controller and Chief Accounting Officer at BOSTON SCIENTIFIC CORP.
“Also on January 26, 2024, the Board appointed Emily Woodworth (Collins), age 46, as Senior Vice President, Global Controller and Chief Accounting Officer, effective March 1, 2024.”
Jonathan Monson was appointed as Senior Vice President, Investor Relations at BOSTON SCIENTIFIC CORP.
“On January 26, 2024, the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) appointed Jonathan Monson as Senior Vice President, Investor Relations, effective March 1, 2024.”
BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Axonics, Inc. valued at Merger consideration of $71.00 per share in cash (effective 2024-01-08).
“On January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Axonics, Inc., a Delaware corporation (“ Axonics ”), providing for the merger of Merger Sub with and into Axonics (the “ Merger ”), with Axonics surviving the Merger as a wholly owned subsidiary of the Company.”
David J. Roux departed as Director at BOSTON SCIENTIFIC CORP.
“On November 16, 2023, David J. Roux informed the Company that he will not stand for re-election at the Company’s 2024 Annual Meeting”
Nelda J. Connors departed as Director at BOSTON SCIENTIFIC CORP.
“On November 16, 2023, Nelda J. Connors informed Boston Scientific Corporation (the “ Company ”) that she will not stand for re-election at the Company’s 2024 Annual Meeting”
BOSTON SCIENTIFIC CORP reported third quarter ended September 30, 2023 results: revenue $3.527 billion, net income $505 million or $0.34 per share, EPS $0.50.
“Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational 1 basis and 10.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted 3 EPS of $0.50 for the period, compared to $0.43 a year ago.”
BOSTON SCIENTIFIC CORP reported the second quarter ended June 30, 2023 results: revenue $3.599 billion, net income $261 million, EPS $0.18 per share (EPS).
“Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational 1 basis and 11.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted 3 EPS of $0.53 for the period, compared to $0.44 a year ago.”
Susan E. Morano was appointed as director at BOSTON SCIENTIFIC CORP.
“appointed each of Jessica L. Mega, MD, MPH and Susan E. Morano to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective June 27, 2023.”
Jessica L. Mega was appointed as director at BOSTON SCIENTIFIC CORP.
“appointed each of Jessica L. Mega, MD, MPH and Susan E. Morano to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective June 27, 2023.”
BOSTON SCIENTIFIC CORP shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor for 2023. at the 2023-05-04 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified. For Against Abstain 1,178,709,166 87,499,383 406,447”
BOSTON SCIENTIFIC CORP shareholders approved Advisory vote on frequency of future advisory votes on executive compensation. at the 2023-05-04 meeting.
“The advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s “Named Executive Officers.” One Year Two Years Three Years Abstain Broker Non-Votes 1,217,156,075 749,405 7,599,630 632,442 40,477,444 Based on the votes set forth above, the Company’s stockholders approved, on a non-binding, advisory basis, a frequency of One Year for the non-binding, advisory vote on the compensation of the Company’s “Named Executive Officers.” The Board considered these voting results and other factors, and determined that the Company will hold future advisory votes on its executive compensation on an annual basis.”
BOSTON SCIENTIFIC CORP shareholders approved Advisory vote on compensation of named executive officers. at the 2023-05-04 meeting.
“The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting was approved. For Against Abstain Broker Non-Votes 1,134,910,823 90,354,176 872,553 40,477,444”
BOSTON SCIENTIFIC CORP shareholders approved Election of nine director nominees to serve until the 2024 Annual Meeting. at the 2023-05-04 meeting.
“All nine director nominees were elected to the Company’s Board of Directors (the “Board”) for a one-year term to hold office until the Company’s 2024 Annual Meeting of Stockholders and until their successors have been elected and qualified. Nominee For Against Abstain Broker Non-Votes Nelda J. Connors 1,193,844,995 31,804,972 487,585 40,477,444 Charles J. Dockendorff 1,150,969,582 74,573,819 594,151 40,477,444 Yoshiaki Fujimori 1,213,401,876 12,156,923 578,753 40,477,444 Edward J. Ludwig 1,179,968,074 45,599,337 570,141 40,477,444 Michael F. Mahoney 1,148,531,592 77,041,192 564,768 40,477,444 David J. Roux 1,182,485,636 43,072,351 579,565 40,477,444 John E. Sununu 1,052,908,443 172,703,257 525,852 40,477,444 David S. Wichmann 1,213,001,870 12,535,441 600,241 40,477,444 Ellen M. Zane 1,062,082,525 163,593,247 461,780 40,477,444”
BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2023 results: revenue $3.389 billion, net income $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS, EPS $0.21 per share.
“RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 Marlborough, Mass. (April 26, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational 1 basis and 14.0 percent on an organic 2 basis, all compared to the”
Donna A. James departed as Director at BOSTON SCIENTIFIC CORP.
“On January 29, 2023, Donna A. James informed the Company that she will not stand for re-election at the Company’s 2023 Annual Meeting.”
Michael Jones changed role as senior vice president and president, Endoscopy at BOSTON SCIENTIFIC CORP.
“Michael Jones, currently senior vice president and general manager, Endoscopy, will change roles and serve as senior vice president and president, Endoscopy.”
Arthur C. Butcher changed role as executive vice president and group president, MedSurg and Asia Pacific at BOSTON SCIENTIFIC CORP.
“Arthur C. Butcher, currently executive vice president and president, Asia Pacific, will change roles and serve as executive vice president and group president, MedSurg and Asia Pacific”
David A. Pierce departed as executive vice president and president, MedSurg and president, Endoscopy at BOSTON SCIENTIFIC CORP.
“On March 30, 2022, David A. Pierce, executive vice president and president, MedSurg and president, Endoscopy, informed Boston Scientific Corporation (“Boston Scientific” or the “Company”), that he will retire, effective July 4, 2022.”
David S. Wichmann was appointed as Director at BOSTON SCIENTIFIC CORP.
“On June 24, 2021, Boston Scientific Corporation (the “Company”) filed a Current Report on Form 8-K announcing the appointment of David S. Wichmann to the Company’s Board of Directors (the “Board”) on June 23, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.